A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
This study is to determine the appropriate dosing regimen of GS-9820 in subjects with
 lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study
 evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.
Inclusion Criteria:

 -  Previously treated recurrent B-cell iNHL, DLBCL, MCL, HL or CLL

 -  Measurable lymphadenopathy

 -  Requires therapy

 Exclusion Criteria:

 -  Recent history of a major non-lymphoid malignancy

 -  Evidence of ongoing infection

 -  Concurrent participation in another therapeutic clinical trial